Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sapacitabine - Daiichi Sankyo Company

X
Drug Profile

Sapacitabine - Daiichi Sankyo Company

Alternative Names: CS-682; CYC-682

Latest Information Update: 08 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company; Hokkaido University; Kanazawa University
  • Developer Cyclacel Pharmaceuticals; Leukaemia & Lymphoma Research; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Arabinonucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Antimetabolites; Cell cycle inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 14 Apr 2023 Safety, efficacy and pharmacodynamics data froma phase Ib/II trial in Breast cancer presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 23 Mar 2023 Cyclacel Pharmaceuticals terminates its licence for sapacitabine with Daiichi Sankyo
  • 09 Nov 2022 Cyclacel Pharmaceuticals plans to terminate license agreement with Daiichi Sankyo in March 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top